DAILY-EQUITY-REPORT BY EPIC RESEARCH 27 FEB 2013
-
Upload
epic-research-private-limited -
Category
Documents
-
view
219 -
download
0
description
Transcript of DAILY-EQUITY-REPORT BY EPIC RESEARCH 27 FEB 2013
-=6 HEADLINES
Indian Market
Indian equity markets were down 1.60%
Nifty down by 93.40 pts and settle at 5761.35
Sensex down by 299.73 pts at 19031.96
Bank Nifty down by 198.90 pts at 11854.00
Global Market
European markets were down with FTSE down by 75.08 closed at 6280 ,CAC down by 70.29 closed at 3651 and DAX down by 134.82 closed at 7638.
Dow future was up 39.00 closed at
14006.00
WWW.EPICRESEARCH.CO 09752199966
DAILY EQUITY NEWSLETTER
27TH FEBRUARY 2013
HEADLINES
• Kingfisher down 5% after govt cancels
international flying rights
• Nifty, S&P fall short-term, but not
reversal in trend: CLSA
• Primary market to get more FII flows;
see lukewarm Budget
• Bharti, Idea rally on hopes of cut in
airwave prices
FII’s and DII’s
CATEGORY DATE BUY SELL NET
FII 26-Feb-13 3150.24 3075.56 74.68
DII 26-Feb-13 1213.8 1374.41 -160.61
NIFTY DAILY PIVOTS
PIVOT R4 R3 R2 R1 PP S1 S2 S3 S4
NIFTY 6052 5962 5872 5816 5782 5726 5692 5602 5512
WWW.EPICRESEARCH.CO 09752199966
MARKET ANALYSIS:
Key benchmark indices slumped after the Minister of Railways Mr. Pawan Kumar Bansal announced
fuel adjustment component (FAC) linked revision for freight tariff to be implemented with effect from
1 April 2013, in Railway Budget for 2013-14. The barometer index, the S&P BSE Sensex, regained the
psychological 19,000 level soon after falling below that mark in late trade.
S&P BSE Sensex was down 299.73 points or 1.55% to 19,031.96
CNX Nifty was down 87.25 points or 1.49% to 5,767.50, as per provisional figures.
Among the 30-share Sensex pack, 25 stocks fell while the rest of them rose.
Index heavyweight and cigarette maker ITC reversed intraday gains in late trade. Another index
heavyweight Reliance Industries (RIL) extended intraday losses in late trade. Auto stocks dropped.
Steel and cement stocks declined after the Minister for Railways Pawan Kumar Bansal today, 26
February 2013, announced fuel adjustment component (FAC) linked revision for freight tariff to be
implemented with effect from 1 April 2013. Ranbaxy Laboratories dropped after Q4 results. Weakness
in global stocks weighed on the domestic bourses. Stocks fell across the globe as political paralysis in
Italy after its general elections fueled fears of renewed instability in Europe, scaring investors out of
risky assets. Auto stocks dropped. Auto companies will start unveiling monthly sales volume data for
February 2013 from Friday, 1 March 2013. India's largest motorcycle maker by sales, Hero MotoCorp,
skidded 0.78%.
STOCKS TO WATCH
ANDHRA BANK
AUROBINDO PHARMA
TCS
INFOSYS
SCRIPS IN BAN PERIOD
IFCI
PUNJLYOD
RENUKA
WWW.EPICRESEARCH.CO 09752199966
.
EXPERT OPINION
NIFTY
Nifty looks Consolidate
Strategy: Sell on rise
Support: 5700
Resistance: 5800
BANK NIFTY
Bank Nifty looks Consolidate
Strategy: Sell on rise
Support: 11800
Resistance: 11910
460
.0
GAINERS AND LOOSERS
PREVIOUS PERFORMANCE
TYPE SCRIP B/S RESULT
CASH AUROBINDO
PHARMA S TARGET HIT
CASH JAIPRAKASH ASSOCIATE
S NOT
EXECUTED
FUTURE ADANI S TARGET HIT
FUTURE AMBUJA B NOT
EXECUTED
UPCOMING RESULTS
BOSCH
CASTROL
ELANTAS BECK
DAILY NIFTY GAINERS
SCRIPS RATE VOL.
(000)
PR.
CLOSE
NET
CHAN
GE
%
CHANG
E
Bharti Airtel
311.80 10760.28 307.00 4.80 1.56
TCS 1496.40 1426.84 1473.70 22.70 1.54
Infosys 2959.80 1521.69 2917.80 42.00 1.44
Grasim 3047.95 94.26 3022.50 25.45 0.84
NTPC 151.00 12907.52 149.85 1.15 0.77
DAILY NIFTY LOOSERS
SCRIPS RATE VOL.
(000)
PR.
CLOSE
NET
CHAN
GE
%
CHAN
GE
Hindalco 101.75 12356.63 106.65 -4.90 -4.59
Bajaj Auto
1921.60 364.90 2009.55 -87.95 -4.38
Ranbaxy Labs.
416.70 1924.87 433.85 -17.15 -3.95
HDFC 771.55 3054.51 802.05 -30.50 -3.80
ONGC 306.35 2909.46 317.90 -11.55 -3.63
.
MARKET CALLS
CASH
SCRIPS ACTION LEVEL 1ST
TARGET 2ND
TARGET STOP LOSS
ANDHRA BANK SELL 94.00 93.50 92.75 94.50
VOLTAS SELL 82.80 81.80 80.30 83.80
FUTURE
SCRIPS ACTION LEVEL 1ST
TARGET 2ND
TARGET STOP LOSS
ALLAHBAD BANK SELL 142.50 141.50 140.50 143.50
AUROBINDO PHARMA
SELL 170.50 169.50 168.50 171.50
Disclaimer
The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most.
Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable.
This material is for personal information and based upon it & takes no responsibility
The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. Epic research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Epic research shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of NSE and BSE.
The share price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. Analyst or any person related to epic research might be holding positions in the stocks recommended. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for . Any surfing and reading of the information is the acceptance of this disclaimer.
All Rights Reserved. Investment in equity & bullion market has its own risks.
We, however, do not vouch for the accuracy or the completeness thereof. we are not responsible for any loss incurred whatsoever for any financial profits or loss which may arise from the recommendations above epic research does not purport to be an invitation or an offer to buy or sell any financial instrument. Our Clients (Paid Or Unpaid), Any third party or anyone else have no rights to forward or share our calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly or indirectly by them. If found so then Serious Legal Actions can be taken.